Lai Shan Tam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/674958/publications.pdf

Version: 2024-02-01

294 papers 10,969 citations

28190 55 h-index 90 g-index

302 all docs 302 docs citations

302 times ranked 11895 citing authors

#	Article	IF	CITATIONS
1	Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clinical Immunology, 2008, 127, 385-393.	1.4	457
2	The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest, 2005, 128, 2247-2261.	0.4	294
3	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 2018, 77, 1295-1302.	0.5	275
4	Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus, 2001, 10, 93-96.	0.8	244
5	Cardiovascular risk profile of patients with psoriatic arthritis compared to controlsthe role of inflammation. Rheumatology, 2008, 47, 718-723.	0.9	225
6	Accrual of organ damage over time in patients with systemic lupus erythematosus. Journal of Rheumatology, 2003, 30, 1955-9.	1.0	218
7	Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology, 2006, 45, 951-957.	0.9	203
8	Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical Rheumatology, 2007, 26, 1495-1498.	1.0	192
9	IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Frontiers in Immunology, 2019, 10, 364.	2.2	191
10	Serum and Urinary Cell–free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2516-2522.	1.0	174
11	Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus, 2011, 20, 829-836.	0.8	174
12	Pathogenesis of ankylosing spondylitis. Nature Reviews Rheumatology, 2010, 6, 399-405.	3.5	169
13	Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2006, 65, 209-215.	0.5	160
14	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
15	Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. Arthritis and Rheumatism, 2004, 50, 3619-3625.	6.7	145
16	Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus, 2011, 20, 493-500.	0.8	142
17	ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clinical Pharmacology and Therapeutics, 2010, 87, 558-562.	2.3	134
18	Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis and Rheumatism, 2008, 59, 1322-1331.	6.7	126

#	Article	IF	CITATIONS
19	Elevated Production of B Cell Chemokine CXCL13 is Correlated with Systemic Lupus Erythematosus Disease Activity. Journal of Clinical Immunology, 2010, 30, 45-52.	2.0	120
20	Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology, 2005, 44, 989-994.	0.9	119
21	Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scandinavian Journal of Rheumatology, 2002, 31, 296-300.	0.6	117
22	Tacrolimus for the treatment of systemic lupus erythematosus with pure class \mbox{V} nephritis. Rheumatology, 2008, 47, 1678-1681.	0.9	115
23	Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus, 2004, 13, 601-604.	0.8	105
24	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5302-11.	3.3	105
25	Leflunomide in the treatment of rheumatoid arthritis. Clinical Therapeutics, 2004, 26, 447-459.	1.1	102
26	The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Frontiers in Medicine, 2021, 8, 743180.	1.2	100
27	Glomerular and tubulointerstitial miRâ€638, miRâ€198 and miRâ€146a expression in lupus nephritis. Nephrology, 2012, 17, 346-351.	0.7	99
28	Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?. Rheumatology, 2014, 53, 1108-1119.	0.9	98
29	Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology, 2005, 44, 602-606.	0.9	93
30	Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R129.	1.6	92
31	The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 1159-1167.	6.7	85
32	Costâ€ofâ€illness studies in systemic lupus erythematosus: A systematic review. Arthritis Care and Research, 2011, 63, 751-760.	1.5	84
33	The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology, 2009, 48, 1491-1497.	0.9	79
34	CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 257-264.	1.0	78
35	Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clinical Rheumatology, 2012, 31, 435-440.	1.0	77
36	Effect of immunosuppressive therapy on interferon \hat{l}^3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax, 2016, 71, 64-72.	2.7	77

#	Article	IF	CITATIONS
37	Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Australian and New Zealand Journal of Medicine, 1995, 25, 258-258.	0.5	76
38	Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis and Rheumatism, 2004, 50, 2882-2890.	6.7	73
39	Intrarenal cytokine gene expression in lupus nephritis. Annals of the Rheumatic Diseases, 2007, 66, 886-892.	0.5	72
40	Safety and efficacy of ⟨i⟩Ganoderma lucidum⟨/i⟩ (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: A doubleâ€blind, randomized, placeboâ€controlled pilot trial. Arthritis and Rheumatism, 2007, 57, 1143-1150.	6.7	71
41	Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus — A Prospective Cohort Study. Journal of Rheumatology, 2010, 37, 330-340.	1.0	71
42	Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut, 2020, 69, 617-629.	6.1	71
43	Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clinical and Experimental Immunology, 2002, 130, 345-351.	1.1	69
44	Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis and Rheumatism, 2003, 48, 1326-1331.	6.7	69
45	Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-î±-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of Ethnopharmacology, 2011, 137, 457-468.	2.0	69
46	Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clinical and Experimental Immunology, 2009, 159, 11-22.	1.1	68
47	Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology, 2009, 48, 892-898.	0.9	64
48	Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A Highâ€Resolution Peripheral Quantitative Computed Tomography Study. Arthritis Care and Research, 2017, 69, 1156-1163.	1.5	64
49	Long-term treatment of lupus nephritis with cyclosporin A. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 573-580.	0.2	63
50	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	2.5	62
51	Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. Journal of Rheumatology, 2007, 34, 89-96.	1.0	62
52	High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 1646-1652.	1.0	60
53	Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. British Journal of Rheumatology, 2003, 42, 117-122.	2.5	59
54	2018 APLAR axial spondyloarthritis treatment recommendations. International Journal of Rheumatic Diseases, 2019, 22, 340-356.	0.9	59

#	Article	IF	CITATIONS
55	Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus, 2008, 17, 1096-1102.	0.8	58
56	Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology, 2020, 59, 2340-2349.	0.9	58
57	Oral Prednisolone in the Treatment of Acute Gout. Annals of Internal Medicine, 2016, 164, 464.	2.0	57
58	Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	56
59	Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Annals of the Rheumatic Diseases, 2006, 65, 417-418.	0.5	55
60	Acupuncture in the treatment of rheumatoid arthritis: a double-blind controlled pilot study. BMC Complementary and Alternative Medicine, 2007, 7, 35.	3.7	55
61	Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis — A Randomized Trial. Journal of Rheumatology, 2012, 39, 2267-2275.	1.0	55
62	Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology, 2008, 48, 564-568.	0.9	54
63	Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Annals of the Rheumatic Diseases, 2011, 70, 705-706.	0.5	53
64	High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2011, 38, 1363-1370.	1.0	53
65	Cardiovascular Risk in Patients with Psoriatic Arthritis. International Journal of Rheumatology, 2012, 2012, 1-11.	0.9	53
66	Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Frontiers in Medicine, 2018, 4, 262.	1.2	53
67	Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology, 2008, 47, 1358-1363.	0.9	50
68	Gene expression of TWEAK/Fn14 and IPâ€10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology, 2011, 16, 426-432.	0.7	50
69	Elevated Expression and Pro-Inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. Molecules, 2015, 20, 19588-19604.	1.7	50
70	Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology, 2006, 46, 649-652.	0.9	49
71	Psoriatic arthritis in Asia. Rheumatology, 2009, 48, 1473-1477.	0.9	47
72	Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice. Clinical and Experimental Immunology, 2015, 181, 253-266.	1.1	47

#	Article	IF	CITATIONS
73	The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrology Dialysis Transplantation, 2006, 21, 1534-1540.	0.4	46
74	Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology, 2008, 47, 1422-1425.	0.9	46
75	Structure and strength of the distal radius in female patients with rheumatoid arthritis: A case-control study. Journal of Bone and Mineral Research, 2013, 28, 794-806.	3.1	46
76	Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. British Journal of Rheumatology, 1998, 37, 405-410.	2.5	45
77	Alterations of Bone Density, Microstructure, and Strength of the Distal Radius in Male Patients With Rheumatoid Arthritis: A Case-Control Study With HR-pQCT. Journal of Bone and Mineral Research, 2014, 29, 2118-2129.	3.1	45
78	The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial. Rheumatology, 2014, 53, 1065-1074.	0.9	45
79	Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology, 2010, 49, 1495-1501.	0.9	44
80	Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case–control study using HR-pQCT. Osteoporosis International, 2013, 24, 1817-1826.	1.3	44
81	Imaging of sacroiliitis: Current status, limitations and pitfalls. Quantitative Imaging in Medicine and Surgery, 2019, 9, 318-335.	1.1	44
82	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology, 2021, 60, 2109-2121.	0.9	44
83	Severe Acute Respiratory Syndrome: Correlation between Clinical Outcome and Radiologic Features. Radiology, 2004, 233, 579-585.	3.6	43
84	Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Annals of the Rheumatic Diseases, 2017, 76, 1237-1244.	0.5	43
85	Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. Journal of Rheumatology, 2007, 34, 2358-64.	1.0	43
86	Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. Clinical Rheumatology, 2007, 26, 941-946.	1.0	42
87	Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern. Journal of Rheumatology, 2010, 37, 1214-1220.	1.0	42
88	Measuring Disease Activity in Psoriatic Arthritis. International Journal of Rheumatology, 2012, 2012, 1-10.	0.9	42
89	Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and Genomics, 2010, 20, 634-637.	0.7	41
90	Relationship Between Flare and Health-related Quality of Life in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 568-573.	1.0	41

#	Article	IF	Citations
91	Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian Journal of Rheumatology, 2011, 40, 411-421.	0.6	41
92	Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology, 2012, 51, 2215-2223.	0.9	40
93	Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Research and Therapy, 2015, 17, 75.	1.6	40
94	Pattern and trend of five major musculoskeletal disorders in China from 1990 to 2017: findings from the Global Burden of Disease Study 2017. BMC Medicine, 2021, 19, 34.	2.3	40
95	Repeat Renal Biopsy in Lupus Nephritis: A Change in Histological Pattern Is Common. American Journal of Nephrology, 2011, 34, 220-225.	1.4	39
96	In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice. Immunobiology, 2017, 222, 483-493.	0.8	39
97	Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatology, 2008, 48, 53-56.	0.9	38
98	Urinary sediment ICAM-1 level in lupus nephritis. Lupus, 2012, 21, 1190-1195.	0.8	38
99	SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus, 2013, 22, 1162-1168.	0.8	38
100	Psoriatic arthritis as a distinct disease entity. Journal of Postgraduate Medicine, 2007, 53, 63-71.	0.2	38
101	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clinical Rheumatology, 2011, 30, 303-312.	1.0	37
102	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and InÂVivo Correction. American Journal of Human Genetics, 2020, 107, 882-894.	2.6	37
103	The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. Journal of Rheumatology, 2008, 35, 1038-45.	1.0	37
104	Disease chronicity and activity predict subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus. Heart, 2009, 95, 980-987.	1.2	36
105	Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus, 2000, 9, 413-416.	0.8	34
106	Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology, 2007, 46, 44-48.	0.9	34
107	Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Research and Therapy, 2010, 12, R198.	1.6	34
108	Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Translational Research, 2016, 167, 138-151.	2.2	34

#	Article	IF	CITATIONS
109	Bone Mineral Density Change in Systemic Lupus Erythematosus: A 5-year Followup Study. Journal of Rheumatology, 2014, 41, 1990-1997.	1.0	33
110	Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology, 2022, 61, 4437-4444.	0.9	33
111	Activation Profile of Intracellular Mitogen-Activated Protein Kinases in Peripheral Lymphocytes of Patients with Systemic Lupus Erythematosus. Journal of Clinical Immunology, 2009, 29, 738-746.	2.0	32
112	Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study. Arthritis Care and Research, 2011, 63, 269-276.	1.5	32
113	Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. Lupus, 2015, 24, 1257-1266.	0.8	32
114	IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. Seminars in Arthritis and Rheumatism, 2015, 45, 18-27.	1.6	32
115	High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease. Frontiers in Medicine, 2020, 7, 337.	1.2	32
116	Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology, 2018, 57, 563-571.	0.9	31
117	Analgesic and anti-arthritic effects of Lingzhi and San Miao San supplementation in a rat model of arthritis induced by Freund's complete adjuvant. Journal of Ethnopharmacology, 2008, 120, 44-50.	2.0	30
118	Urinary FOXP3 mRNA in patients with lupus nephritis-relation with disease activity and treatment response. Rheumatology, 2009, 48, 755-760.	0.9	29
119	Bone Density and Microarchitecture: Relationship Between Hand, Peripheral, and Axial Skeletal Sites Assessed by HR-pQCT and DXA in Rheumatoid Arthritis. Calcified Tissue International, 2012, 91, 343-355.	1.5	29
120	Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. Rheumatology, 2010, 49, 112-115.	0.9	28
121	Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, R80.	1.6	28
122	Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study. Osteoporosis International, 2015, 26, 1759-1771.	1.3	28
123	Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scandinavian Journal of Rheumatology, 2003, 32, 306-308.	0.6	27
124	Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus, 2003, 12, 665-671.	0.8	27
125	SLICC/ACR damage index independently associated with left ventricular diastolic dysfunction in patients with systemic lupus erythematosus. Lupus, 2012, 21, 1057-1062.	0.8	27
126	Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. Nephrology, 2006, 11, 219-225.	0.7	26

#	Article	IF	CITATIONS
127	Bone Microarchitecture Assessment by High-Resolution Peripheral Quantitative Computed Tomography in Patients with Systemic Lupus Erythematosus Taking Corticosteroids. Journal of Rheumatology, 2010, 37, 1473-1479.	1.0	26
128	Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia. Journal of Rheumatology, 2003, 30, 1479-84.	1.0	26
129	Hemiballismus in systemic lupus erythematosus: possible association with antiphospholipid antibodies. Lupus, 1995, 4, 67-69.	0.8	25
130	Immunomodulatory Effects of Lingzhi and San-Miao-San Supplementation on Patients with Rheumatoid Arthritis. Immunopharmacology and Immunotoxicology, 2006, 28, 197-200.	1.1	25
131	Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clinical Rheumatology, 2017, 36, 485-497.	1.0	25
132	A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. Journal of Crohn's and Colitis, 2018, 12, 954-962.	0.6	25
133	Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. Journal of Rheumatology, 2008, 35, 1613-21.	1.0	25
134	Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clinical and Experimental Immunology, 2003, 133, 132-138.	1.1	24
135	Urinary mononuclear cell and disease activity of systemic lupus erythematosus. Lupus, 2006, 15, 262-267.	0.8	24
136	Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Rheumatology, 2011, 50, 1293-1301.	0.9	24
137	Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. Cellular and Molecular Immunology, 2011, 8, 469-478.	4.8	24
138	Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 271-280.	2.9	24
139	Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Seminars in Arthritis and Rheumatism, 2020, 50, 885-889.	1.6	24
140	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVIDâ€19 pandemic. International Journal of Rheumatic Diseases, 2021, 24, 733-745.	0.9	24
141	Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Lupus, 1998, 7, 495-497.	0.8	23
142	Lupus organ damage: what is damaged in Asian patients?. Lupus, 2010, 19, 1436-1441.	0.8	23
143	The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2013, 9, 739-749.	1.3	23
144	Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2018, 45, 218-226.	1.0	23

#	Article	IF	CITATIONS
145	Anti-inflammatory activities of Ganoderma lucidum (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus. Chinese Medicine, 2016, 11, 23.	1.6	22
146	Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Annals of the Rheumatic Diseases, 2021, 80, e97-e97.	0.5	22
147	Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clinical and Experimental Rheumatology, 2010, 28, 679-85.	0.4	22
148	Serum Soluble Receptor for Advanced Glycation End Products Levels and Aortic Augmentation Index in Early Rheumatoid Arthritis—A Prospective Study. Seminars in Arthritis and Rheumatism, 2013, 42, 333-345.	1.6	21
149	Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus, 2015, 24, 675-686.	0.8	21
150	Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. Rheumatology, 2019, 58, 803-810.	0.9	21
151	Care for patients with rheumatic diseases during COVIDâ€19 pandemic: A position statement from APLAR. International Journal of Rheumatic Diseases, 2020, 23, 717-722.	0.9	21
152	Density, structure, and strength of the distal radius in patients with psoriatic arthritis: the role of inflammation and cardiovascular risk factors. Osteoporosis International, 2015, 26, 261-272.	1.3	20
153	Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210895.	1.2	20
154	Decreased Expression of T Lymphocyte Co-Stimulatory Molecule CD26 on Invariant Natural Killer T Cells in Systemic Lupus Erythematosus. Immunological Investigations, 2009, 38, 350-364.	1.0	19
155	Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. PLoS ONE, 2011, 6, e23855.	1.1	19
156	DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. Annals of the Rheumatic Diseases, 2020, 79, 1320-1326.	0.5	18
157	Gut Microbiome and Its Interaction with Immune System in Spondyloarthritis. Microorganisms, 2020, 8, 1727.	1.6	18
158	Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong. Journal of Rheumatology, 2008, 35, 1031-7.	1.0	18
159	The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. Journal of Lipid Research, 2012, 53, 1384-1389.	2.0	17
160	Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 706-713.	1.0	17
161	Factors associated with withdrawal of the antiâ€ <scp>TNF</scp> α biologics in the treatment of rheumatic diseases: data from the <scp>H</scp> ong <scp>K</scp> ong <scp>B</scp> iologics <scp>R</scp> egistry. International Journal of Rheumatic Diseases, 2014, 17, 1-8.	0.9	17
162	Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese Medicine, for patients with osteoarthritis of the knee: a multi-site, randomized, double-blind, placebo-controlled phase II clinical trial. Osteoarthritis and Cartilage, 2015, 23, 2102-2108.	0.6	17

#	Article	IF	Citations
163	Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in Psoriatic Arthritis. Journal of Rheumatology, 2012, 39, 844-848.	1.0	16
164	Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2. Scientific Reports, 2016, 6, 32116.	1.6	16
165	Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. Rheumatology, 2020, 59, 3172-3180.	0.9	16
166	Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus, 2001, 10, 827-829.	0.8	15
167	The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. Journal of Rheumatology, 2007, 34, 1032-9.	1.0	15
168	Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. Lupus, 2006, 15, 276-281.	0.8	14
169	Increased Organ Damage Associated with Deterioration in Volumetric Bone Density and Bone Microarchitecture in Patients with Systemic Lupus Erythematosus on Longterm Glucocorticoid Therapy. Journal of Rheumatology, 2012, 39, 1955-1963.	1.0	14
170	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. Journal of Rheumatology, 2015, 42, 1150-1155.	1.0	14
171	A pilot evaluation of Arthritis Self-Management Program by lay leaders in patients with chronic inflammatory arthritis in Hong Kong. Clinical Rheumatology, 2016, 35, 935-941.	1.0	14
172	Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study. Journal of Rheumatology, 2018, 45, 1229-1239.	1.0	14
173	Circulating miRâ€99bâ€5p as a novel predictor of erosion progression on highâ€resolution peripheral quantitative computed tomography in early rheumatoid arthritis: A prospective cohort study. International Journal of Rheumatic Diseases, 2019, 22, 1724-1733.	0.9	14
174	The Perspective on Psoriatic Arthritis in Asia. Current Rheumatology Reports, 2011, 13, 369-375.	2.1	13
175	Relationship of Intrarenal Gene Expression and the Histological Class of Lupus Nephritis — A Study on Repeat Renal Biopsy. Journal of Rheumatology, 2012, 39, 1942-1947.	1.0	13
176	Labour and non-labour market productivity in Chinese patients with systemic lupus erythematosus. Rheumatology, 2012, 51, 284-292.	0.9	13
177	Monitoring of urinary messenger RNA levels for the prediction of flare in systemic lupus erythematosus. Clinica Chimica Acta, 2012, 413, 448-455.	0.5	13
178	Development and Assessment of Users' Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. Journal of Rheumatology, 2013, 40, 34-39.	1.0	13
179	Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study. Seminars in Arthritis and Rheumatism, 2018, 48, 374-383.	1.6	13
180	Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients with Psoriatic Arthritis Receiving Tumor Necrosis Factor-α Blockers. Journal of Rheumatology, 2011, 38, 2077.2-2079.	1.0	12

#	Article	IF	CITATIONS
181	Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study. BMC Musculoskeletal Disorders, 2014, 15, 284.	0.8	12
182	Incidence of and risk factors for non-vertebral and vertebral fracture in female Chinese patients with systemic lupus erythematosus: a five-year cohort study. Lupus, 2014, 23, 854-861.	0.8	12
183	Dyslipidemia Is Related to Mortality in Critical Patients With Coronavirus Disease 2019: A Retrospective Study. Frontiers in Endocrinology, 2021, 12, 611526.	1.5	12
184	Neurotoxicity following the ingestion of a Chinese medicinal plant, Alocasia macrorrhiza. Human and Experimental Toxicology, 1995, 14, 727-728.	1.1	11
185	Decreased ex vivo production of TNF-α and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. International Immunopharmacology, 2007, 7, 1668-1677.	1.7	11
186	Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. Clinical Rheumatology, 2011, 30, 1157-1162.	1.0	11
187	Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An <scp>A</scp> sian perspective. Respirology, 2013, 18, 765-773.	1.3	11
188	Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid. Rheumatology International, 2005, 25, 388-390.	1.5	10
189	The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 53-69.	0.7	10
190	Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. ERJ Open Research, 2018, 4, 00135-2017.	1.1	10
191	Bone Mass, Microstructure, and Strength Can Discriminate Vertebral Fracture in Patients on Long-Term Steroid Treatment. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3340-3349.	1.8	10
192	Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity?. Journal of Rheumatology, 2005, 32, 828-31.	1.0	10
193	Dynamic contrast-enhanced imaging of the wrist in rheumatoid arthritis: dedicated low-field (0.25-T) versus high-field (3.0-T) MRI. Skeletal Radiology, 2015, 44, 1095-1101.	1.2	9
194	Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with Osteoarthritis and Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 563-573.	1.0	9
195	Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study. Arthritis Research and Therapy, 2019, 21, 265.	1.6	9
196	Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. Osteoporosis International, 2020, 31, 941-950.	1.3	9
197	A Microwave–Ultrasonic Cell for Sound-Speed Measurements in Liquids. International Journal of Thermophysics, 2005, 26, 1651-1665.	1.0	8
198	Clinical presentation, treatment and outcome of Takayasu's arteritis in southern Chinese: a multicenter retrospective study. Rheumatology International, 2018, 38, 2263-2270.	1.5	8

#	Article	IF	CITATIONS
199	The role of imaging in early diagnosis and prevention of joint damage in inflammatory arthritis. Expert Review of Clinical Immunology, 2018, 14, 499-511.	1.3	8
200	Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096261.	1.2	8
201	Cardiovascular disease and depression in psoriatic arthritis: Multidimensional comorbidities requiring multidisciplinary management. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101689.	1.4	8
202	Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110277.	1.2	8
203	The Role of High-resolution Peripheral Quantitative Computed Tomography as a Biomarker for Joint Damage in Inflammatory Arthritis. Journal of Rheumatology, 2016, 43, 1911-1913.	1.0	7
204	No Systemic Lupus Erythematosus with COVID-19 in Hong Kong: The Effect of Masking?. Journal of Rheumatology, 2020, 47, 1591-1591.	1.0	7
205	Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis—which target should we choose?. Rheumatology, 2020, 59, 2881-2892.	0.9	7
206	Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 981-988.	0.5	7
207	Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus. Clinical Chemistry, 2022, 68, 917-926.	1.5	7
208	Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial. Lupus, 2022, 31, 488-494.	0.8	7
209	Stonefish sting: an occupational hazard in Hong Kong. Annals of Tropical Medicine and Parasitology, 1996, 90, 675-676.	1.6	6
210	ERAMRS: a new MR scoring system for early rheumatoid arthritis of the wrist. European Radiology, 2019, 29, 5646-5654.	2.3	6
211	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology, 2019, 46, 1406-1408.	1.0	6
212	Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. RMD Open, 2020, 6, e001364.	1.8	6
213	Vertebral body corner oedema <i>vs</i> gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis. British Journal of Radiology, 2012, 85, e702-e708.	1.0	5
214	Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis. Frontiers in Medicine, 2022, 9, 837024.	1.2	5
215	Urinary mRNA in Systemic Lupus Erythematosus. Advances in Clinical Chemistry, 2013, 62, 197-219.	1.8	4
216	Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology. International Journal of Rheumatic Diseases, 2013, 16, 500-508.	0.9	4

#	Article	IF	CITATIONS
217	Computerâ€Aided Assessment of Spinal Inflammation on Magnetic Resonance Images in Patients With Spondyloarthritis. Arthritis and Rheumatology, 2015, 67, 1789-1797.	2.9	4
218	Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases. Asia-Pacific Journal of Ophthalmology, 2015, 4, 19-24.	1.3	4
219	The causal effect of interleukin-17 on the risk of psoriatic arthritis: a Mendelian randomization study. Rheumatology, 2021, 60, 1963-1973.	0.9	4
220	Elevating the role of carers in rheumatoid arthritis management in the Asiaâ€Pacific region. International Journal of Rheumatic Diseases, 2020, 23, 898-910.	0.9	3
221	MRI wrist in early rheumatoid arthritis: reduction in inflammation assessed quantitatively during treatment period correlates best with clinical improvement. Skeletal Radiology, 2021, 50, 1337-1345.	1.2	3
222	The role of imaging in predicting the development of rheumatoid arthritis. Rheumatology and Immunology Research, 2021, 2, 27-33.	0.2	3
223	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria in Patients With Idiopathic Inflammatory Myopathy and Anti–Melanoma Differentiation–Associated Protein 5 Positivity. Arthritis and Rheumatology, 2022, 74, 1588-1592.	2.9	3
224	Correspondence on †No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related †physician-reported spondylitis†M. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.5	3
225	Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases. Current Opinion in Rheumatology, 2022, 34, 203-208.	2.0	3
226	Metabolic abnormalities associated with microalbuminuria in systemic lupus erythematosus. British Journal of Rheumatology, 2001, 40, 1193-a-1194.	2.5	2
227	Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice, 2018, 2, rky045.	0.3	2
228	The Asiaâ€Pacific Initiative for Rheumatology Nurse Education: Current gaps, programme development and future outlook. Musculoskeletal Care, 2020, 18, 397-403.	0.6	2
229	Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis. Frontiers in Medicine, 0, 9, .	1.2	2
230	Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients. Nature Clinical Practice Nephrology, 2006, 2, 672-673.	2.0	1
231	The direct medical cost of rheumatoid arthritis in Hong Kong. Journal of Medical Economics, 2007, 10, 443-453.	1.0	1
232	FRIO412 $\hat{a}\in$ The effects of golimumab on the progression of subclinical atherosclerosis and arterial stiffness in patients with ankylosing spondylitis $\hat{a}\in$ " a randomized, placebo- controlled trial. Annals of the Rheumatic Diseases, 2013, 72, A513.1-A513.	0.5	1
233	THU0555 Immunopathological Roles of the Novel Anti-Inflammatory Cytokine Interleukin-35 in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 374.2-374.	0.5	1
234	THU0033â€Effects of Early Remission on Work Ability and Absenteeism in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 189.2-189.	0.5	1

#	Article	IF	CITATIONS
235	SAT0073â€MIR-186-5P targeting IL-33 gene as biomarker to predict subclinical atherosclerosis in patients with early rheumatoid arthritis. , 2017, , .		1
236	FRIO523â€Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials. , 2017, , .		1
237	FRI0524â€Carotid atherosclerosis is associated with compromised volumetric bone mineral density and microstructures in patients with inflammatory arthritis. , 2017, , .		1
238	Inflammatory Burden Is Related toÂan Early Reduction of LV Functional Reserve in PsoriaticÂArthritis. JACC: Cardiovascular Imaging, 2018, 11, 369-370.	2.3	1
239	Dr. Tam, et al, reply. Journal of Rheumatology, 2018, 45, 1330-1332.	1.0	1
240	OP0132â€Structural and microstructural intra-articular bone changes at the metacarpal heads in patients with psoriatic arthritis compared to controls: a hr-pqct study. , 2018, , .		1
241	Deception and selfâ€harm in the quest for freedom: an audit of Vietnamese boat people admitted to a regional hospital in Hong Kong. Medical Journal of Australia, 1995, 163, 524-526.	0.8	1
242	FRIO552â€GLOBAL, REGIONAL, AND NATIONAL BURDEN OF LOW BACK PAIN, 1990-2019: A SYSTEMATIC ANALY FOR THE GLOBAL BURDEN OF DISEASE STUDY 2019. Annals of the Rheumatic Diseases, 2020, 79, 877.1-878.	YSIS 0.5	1
243	Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak. Frontiers in Medicine, 2021, 8, 790652.	1.2	1
244	PAR13 THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG. Value in Health, 2005, 8, A27-A28.	0.1	0
245	P336 Subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus (SLE). International Journal of Cardiology, 2008, 125, S61.	0.8	0
246	Are spot urine samples adequate for assessment of proteinuria in patients with lupus nephritis?. Nature Clinical Practice Nephrology, 2008, 4, 72-73.	2.0	0
247	SAT0210â€Comparisons of bone microarchitecture and mechanical properties between childhood- and adult-onset patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 71, 543.1-543.	0.5	O
248	THU0196â€Bone microarchitecture and biomechanical properties in chinese female patients with systemic lupus erythematosus damage. Annals of the Rheumatic Diseases, 2013, 71, 221.3-222.	0.5	0
249	THU0083â€Abnormal volumetric density and microarchitecture at the radius in chinese female patients with rheumatoid arthritis: A case-control study. Annals of the Rheumatic Diseases, 2013, 71, 181.1-181.	0.5	O
250	SAT0397â€Serum Apolipoprotein B is Associated with Increased Risk of the Presence and Progression of Carotid Atherosclerosis in Patients with Psoriatic Arthritis: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 738.1-738.	0.5	0
251	SAT0413â€A Case-Control Study of Density and Microstructure at the Distal Radius in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 744.2-744.	0.5	O
252	SAT0414â€Predictors of Functional Deterioration in Chinese Patients with Psoriatic Arthritis: A Longitudinal Study. Annals of the Rheumatic Diseases, 2014, 73, 744.3-745.	0.5	0

#	Article	IF	CITATIONS
253	THU0570â€A Pilot Evaluation of Arthritis Self-Management Program by Lay Leaders in Patients with Chronic Inflammatory Arthritis in Hong Kong. Annals of the Rheumatic Diseases, 2014, 73, 379.3-380.	0.5	O
254	THU0383â€Aberrant Expression of Novel Pro-Inflammatory Cytokine Interleukin-36 in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study. Annals of the Rheumatic Diseases, 2015, 74, 335.1-335.	0.5	0
255	THU0164â€Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture at the Distal Radius in Rheumatoid Arthritis Females with Low Bone Mass: A Randomized Controlled Trial. Annals of the Rheumatic Diseases, 2015, 74, 253.2-253.	0.5	O
256	ABO811â€Carotid Atherosclerosis is Associated with Compromised Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 1170.3-1171.	0.5	0
257	AB0812 Increased Arterial Stiffness is Associated with Compromised Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 1171.1-1171.	0.5	0
258	Authors' Reply to "Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases― Asia-Pacific Journal of Ophthalmology, 2015, 4, 184.	1.3	0
259	AB0384â€Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture at the 2ND Metacarpal Head in Rheumatoid Arthritis Females with Low Bone Mass by High- Resolution Peripheral Quantitative Computer Tomography: A Randomized Controlled Pilot Trial. Annals of the Rheumatic Diseases. 2015, 74, 1021.2-1021.	0.5	0
260	THU0184â€Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: An HR-pQCT Study:. Annals of the Rheumatic Diseases, 2016, 75, 251.3-252.	0.5	0
261	FRIO455â€All Cardiovascular (CV) Risk Scores Significantly Underestimated Cv Risk Defined by Carotid Ultrasound in Psoriatic Arthritis- Can We Improve Their Performances?. Annals of the Rheumatic Diseases, 2016, 75, 601.1-601.	0.5	0
262	FRI0034â€Rage Activity Influences Co-Development of Joint and Vascular Disease in RA. Annals of the Rheumatic Diseases, 2016, 75, 438.1-438.	0.5	0
263	SAT0141â€Changes of Bone Density and Microarchitecture in Rheumatoid Arthritis Patients with Early Disease: A One-Year Study with HR-PQCT: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 715.2-715.	0.5	0
264	SAT0532â€Tibial Cortical Thickness Measured by Highâ€"Resolution Peripheral Quantitative Computed Tomography Discriminates Vertebral Fractures in Patients on Long-Term Glucocorticoids Independent of Areal Bone Mineral Density: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 862.1-862.	0.5	0
265	IMPAIRED LEFT VENTRICULAR LONGITUDINAL FUNCTIONAL RESERVE IN PATIENTS WITH PSORIATIC ARTHRITIS: A LOW-LEVEL BICYCLE ERGOMETER EXERCISE TEST. Journal of the American College of Cardiology, 2017, 69, 1615.	1.2	0
266	AB1229-HPRâ€Evaluation of rheumatology nurse-led clinic in managing patients with rheumatoid arthritis: a retrospective study. , 2017, , .		0
267	SAT0479 Increased carotid intima-media thickness can discriminate significant coronary artery stenosis by coronary ct angiogram in patients with psoriatic arthritis. , 2017, , .		0
268	Frequent Conversion of Tuberculosis Screening Test During Anti-Tumour Necrosis Factor Therapy in Chinese Patients with Inflammatory Bowel Disease: A Prospective Study with 3 Years Follow-Up. Gastroenterology, 2017, 152, S387.	0.6	0
269	AB0424â€The effect of high level of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with early rheumatoid arthritis– a cross-sectional and longitudinal analysis. , 2017, , .		0
270	AB0221â€Impact of small to medium dose of prednisolone on bone mineral density among early rheumatoid arthritis patients. , 2017, , .		0

#	Article	lF	CITATIONS
271	FRI0576â€Comparing treatment indication by frax and bmd alone in rheumatic patients on long-term glucocorticoid in hong kong. , 2017, , .		O
272	SATO747-HPRâ€Can achieving sustained das remission prevent progression of sub- clinical atherosclerosis? a prospective cohort study in early rheumatoid arthritis (ERA). , 2017, , .		0
273	THU0078 Berberine ameliorates bone erosions in collagen-induced arthritis rat models via suppressing the expression of il-17a. , 2018, , .		O
274	Comment on: Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis: reply. Rheumatology, 2018, 57, 2062-2062.	0.9	0
275	Authors reply to comment on axial SpA recommendations. International Journal of Rheumatic Diseases, 2019, 22, 1346-1347.	0.9	O
276	SAT0364â€EFFECT OF ACHIEVING DAPSA-LDA ON THE PROGRESSION OF BONE EROSION AND ENTHESIOPHYTE IN PATIENTS WITH PSORIATIC ARTHRITIS: A LONGITUDINAL HR-PQCT STUDY., 2019,,.	ES	0
277	THU0264â€ANALYSIS OF SURVIVAL ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WI SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	тн	O
278	FRIO464â€EFFECT OF BIOLOGICS ON ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
279	OP0346â€MRI OF THE WRIST IN EARLY RHEUMATOID ARTHRITIS AFTER 1-YEAR TREAT-TO-TARGET STRATEGY. , 2019, , .		O
280	Spondyloarthritis-Related Autoimmune Aortitis Complicated by Severe Aortic Regurgitation. Circulation: Cardiovascular Imaging, 2019, 12, e008341.	1.3	0
281	SAT0043 ll-33/st2-mediated inflammation in endothelial cell is directly aggravated by il-6 during lupus nephritis. , 2018, , .		O
282	FRIO616â€Cost-effectiveness of swapping strategy for established psoriatic arthritis and immediate versus standard swapping strategy for early psoriatic arthritis., 2018,,.		0
283	SAT0094â€Physical function and health related quality of life in early rheumatoid arthritis patients who achieved only low disease activitycompared with remission., 2018,,.		0
284	THU0179â€Mir-382–5p targeting il-33 gene as biomarker to predict subclinical atherosclerosis progression in patients with early rheumatoid arthritis. , 2018, , .		0
285	FRI0032â€Role of ultrasound in assessing disease activity in patients with early rheumatoid arthritis treated by two treat-to-target strategies. , 2018, , .		0
286	AB1270â€Achieving early disease control and reducing indirect cost – the crystal registry in hong kong rheumatoid arthritis patients. , 2018, , .		0
287	OP0127â€Can achieving minimal disease activity (MDA) prevent progression of subclinical atherosclerosis and arterial stiffness? a two-year prospective cohort study in psoriatic arthritis. , 2018, , .		О
288	SAT0309â€Underestimation of cardiovascular events by cardiovascular risk scores in psoriatic arthritis patients. , 2018, , .		0

#	Article	lF	CITATIONS
289	SAT0656â€Circulating mir-99b-5p is a marker of inflammation and structural damage on mri in early rheumatoid arthritis. , 2018, , .		O
290	FRIO666â€Circulating mir-99b-5p as a predictor of erosion progression in early rheumatoid arthritis: a 1-year follow-up study by hr-pqct. , 2018, , .		O
291	FRI0565â€Eramrs: a new mr scoring system for early rheumatoid arthritis. , 2018, , .		O
292	Approaches to screening for latent tuberculosis infection in patients with immune-mediated disease prior to commencement of biologics., 2020, 26, 93-94.		0
293	SATO408 UTILITY OF CAROTID ULTRASOUND AND FRAMINGHAM RISK SCORE ON DISCRIMINATING CORONARTERY DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA). Annals of the Rheumatic Diseases, 2020, 79, 1156.2-1156.	ARY 0.5	O
294	The Temporal Trend of Disease Burden Attributable to Metabolic Factors in China, 1990-2019, an Analysis of the Global Burden of Disease Study. SSRN Electronic Journal, 0, , .	0.4	0